No Data
China Healthcare Sector to Get Policy Boost in 1Q -- Market Talk
WUXI BIO sells overseas Assets, but not because of the biosecurity legislation.
By adjusting the Assets, WUXI BIO has released more space and will further increase its overseas investments.
[Brokerage Focus] Morgan Stanley reiterates the "Shareholding" rating for WUXI BIO (02269), indicating that the sale of the Haierland facility is beneficial for profitability and ROI.
Jinwu Finance | Morgan Stanley's research report indicates that since the ROI of this asset for WUXI BIO (02269) is below the target, according to the management of WUXI APPTEC, the trade seems to be a win-win situation for both parties. The company's other facilities in Ireland maintain stable operations, with a gross margin of about 40% in the stable phase. Regarding the use of cash earnings, WUXI APPTEC will further buy back shares and invest in higher return opportunities. As the ROI is performing well, there are currently no other assets that need to be sold. The firm expressed that although selling assets will sacrifice the short-term income of WUXI BIO, it believes this trade will be beneficial to the public.
WuXi Biologics (Cayman) Subsidiary to Sell Vaccines Manufacturing Facility in Ireland for $500 Million
[Brokerage Focus] Citigroup assigns a "Buy" rating to WUXI BIO (02269) and states that the sale of the Irish vaccine facility will have no negative impact on finances.
Citi published a research report indicating that WUXI BIO (02269) previously announced the sale of assets related to its vaccine facility in Ireland to Merck (MSD International), with a total price of approximately 0.5 billion USD (about 3.9 billion HKD). The bank stated that while WUXI BIO's divestiture of designated overseas facilities aligns with market expectations, some may view the asset sale as a defensive measure against potential geopolitical risks. The bank believes that the aforementioned transaction concerning the Ireland vaccine facility will not negatively impact the company's finances and will enhance its overall profitability. Citi has set a Target Price for WUXI BIO of
Wuxi Bio's Ireland Facility Sale Likely to Help With Cash Flow -- Market Talk
